Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Proprietary Therapy for Multiple Sclerosis Treatment
June 8, 2026
Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising. Multiple sclerosis remains one of the most challenging neurological diseases facing patients and clinicians because of its progressive nature, unpredictable course and lack of a cure. The disease affects more than 2.8 million people worldwide and approximately 1 million […]
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Builds Diversified Pipeline Across Neurological and Wellness Markets
June 3, 2026
Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising. Neurological disorders are increasingly recognized as one of the world’s most significant healthcare challenges as aging populations and rising disease prevalence place growing pressure on healthcare systems globally. According to the World Health Organization, neurological conditions are now the […]
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Highlights Lucid-MS and unbuzzd(TM) Growth Opportunities on BioMedWire Podcast
June 2, 2026
This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company focused on advancing innovative therapies and technologies, was featured on the latest episode of The BioMedWire Podcast, where co-founder and executive co-chair Anthony Durkacz discussed the company’s lead drug candidate, Lucid-MS. […]
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Engages Stocks.news for Investor Relations Services
June 2, 2026
This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company focused on advancing innovative therapies and technologies, announced that it has entered into an investor relations and consulting services agreement with Stocks.news through IR Agency LLC beginning June 8, 2026. Under the six-month agreement, the agency will provide […]
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Is ‘One to Watch’
May 28, 2026
Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is a biopharmaceutical company focused on developing therapies and biotech solutions targeting neurodegenerative, metabolic and alcohol misuse disorders. The company is advancing a diversified platform spanning clinical-stage therapeutics, consumer-focused wellness products and strategic investments designed […]
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Reports Midpoint Enrollment Milestone in Multiple Sclerosis Imaging Study
May 18, 2026
This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) announced that patient enrollment in its collaborative multiple sclerosis imaging study with Massachusetts General Hospital has reached the halfway mark, with preliminary imaging data showing encouraging signal in acute MS lesions and potential sensitivity […]
InvestorNewsBreaks – IBN Teams with Centri Business Consulting to Support April 14 Capital Conference At Nasdaq
April 2, 2026
IBN (InvestorBrandNetwork) announced its collaboration with Centri Business Consulting for the Centri Capital Conference scheduled for April 14, 2026, at Nasdaq in New York City, where selected high-growth companies will present to investment bankers, private equity and venture capital participants while engaging in one-on-one meetings and panel discussions. As media sponsor, IBN will leverage its InvestorWire distribution network and broader portfolio of […]
InvestorNewsBreaks – US~Observer Investigates Alleged Spoofing Activity Involving Quantum BioPharma (QNTM)
March 11, 2026
Investigative newspaper examines compliance oversight and market manipulation claims tied to CIBC leadership and a $700M lawsuit The US~Observer, an investigative newspaper focused on exposing misconduct in government, finance and law enforcement, has published an article examining alleged market manipulation involving Quantum BioPharma Ltd. (QNTM). The publication reports that the allegations are part of a […]
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Completes 180-Day Toxicity Studies for Lucid-MS
December 23, 2025
This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) reported the completion of oral dosing in both 180-day chronic toxicity and toxicokinetic studies for Lucid-21-302 (Lucid-MS), a key milestone supporting the company’s planned Investigational New Drug application with the U.S. Food and Drug […]
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Highlighted in CTV W5 Part 2 Covering Alleged Market Manipulation
December 1, 2025
This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) said CTV News’ investigative program W5 has aired Part 2 of its three-part series examining the Company’s allegations of stock spoofing tied to its USD $700 million lawsuit against CIBC and RBC. The […]
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Featured in CTV News W5 Series on Stock Manipulation Allegations
December 1, 2025
This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) was the focus of CTV News’ W5 program, which aired Part Three of its investigative series examining the company’s allegations of stock spoofing tied to its USD $700 million lawsuit against CIBC and […]
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Featured in CTV W5 Investigation on Alleged Stock Manipulation
November 26, 2025
This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) said that CTV News’ flagship investigative program W5 is airing a three-part series beginning today that examines the Company and its allegations of stock market manipulation. W5 investigative reporter Jon Woodward introduces Part […]
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Announces Private Placement of Class A Multiple Voting Shares
October 30, 2025
This article has been disseminated on behalf of Quantum BioPharma and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company advancing treatments for neurodegenerative, metabolic, and alcohol misuse disorders, announced a non-brokered private placement of up to 30 Class A multiple voting shares at $25 per share for gross proceeds of up to $750. […]
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Licensee Unbuzzd Wellness to Host Investor Webinar Oct. 30
October 23, 2025
This article has been disseminated on behalf of Quantum BioPharma and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company advancing treatments for neurodegenerative, metabolic, and alcohol misuse disorders, announced that its licensee, Unbuzzd Wellness Inc., will host an investor webinar on Oct. 30, 2025, at 4:15 p.m. ET (1:15 p.m. PT) […]
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Announces Expiration of Final Hedge Fund Warrants and Confirms Oct. 27 CVR Record Date
October 21, 2025
This article has been disseminated on behalf of Quantum BioPharma and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) announced the expiration at 5 p.m. ET of 53,147 warrants (originally 3,454,543 pre-reverse-split warrants) issued to hedge funds and investment funds as part of a 2020 financing, marking the final tranche of such warrants. The […]
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Refutes Unsubstantiated Claims in Law Firm Announcements
October 14, 2025
This article has been disseminated on behalf of Quantum BioPharma and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) issued a formal response rejecting what it described as vague and unsubstantiated claims made by The Schall Law Firm and DJS Law Group regarding alleged securities law violations. The company stated that the announcements lack […]
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Launches Whistleblower Reward Program Offering up to $7 Million for Stock Manipulation Evidence
October 8, 2025
This article has been disseminated on behalf of Quantum BioPharma and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company advancing innovative treatments for neurodegenerative, metabolic, and alcohol misuse disorders, announced the implementation of a public whistleblower policy offering cash rewards of up to USD $7 million for verifiable evidence of stock […]
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Redefines Life Sciences with Digitally Engineered, Multi-Vertical Growth Model
October 7, 2025
This article has been disseminated on behalf of Quantum BioPharma and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is transforming the biotechnology landscape through a digitally integrated model that merges clinical innovation, consumer health commercialization, and market infrastructure modernization. Anchored by its flagship neuroprotective program, Lucid-MS, developed with Massachusetts General Hospital to address […]
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Sets Record Date for Litigation-Linked CVR Distribution
October 3, 2025
This article has been disseminated on behalf of Quantum BioPharma and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) announced that Oct. 27, 2025 has been established as the record date for the distribution of contingent value rights (CVRs) to holders of its Class B Subordinate Voting Shares on a one-for-one basis. Each CVR […]
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances IND Application for Lucid-MS with Final Toxicity Reports
October 2, 2025
This article has been disseminated on behalf of Quantum BioPharma and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) announced it has received final reports from its 90-day oral toxicity and toxicokinetic studies for Lucid-21-302 (“Lucid-MS”), its potential breakthrough drug for Multiple Sclerosis. The results will support the company’s upcoming IND application to the […]
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Appoints Dr. Jack Antel as Clinical Advisor for MS Program
October 1, 2025
This article has been disseminated on behalf of Quantum BioPharma and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) announced the appointment of Dr. Jack Antel, a world-renowned multiple sclerosis (MS) expert and Professor of Neurology at McGill University, as clinical advisor to support the development of Lucid-21-302 (“Lucid-MS”), the Company’s patented investigational drug […]
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Reports Results of Annual General and Special Meeting
September 29, 2025
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) announced the results of its annual general and special meeting of shareholders held Sept. 26, 2025, in Toronto, with shareholders representing 12 Class A multiple voting shares—entitling holders to 276,660 votes per share—and 1,769,228 Class B subordinate voting shares present in person or by proxy, accounting for 100% of […]
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Receives Health Canada Product License for Qlarity
September 18, 2025
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company developing treatments for neurodegenerative and metabolic disorders and alcohol misuse, announced that Health Canada has granted a Product License (PN 80144141) for its natural health product, Qlarity. The license permits sale of Qlarity in Canada with recommended uses including supporting energy production, metabolism, electrolyte balance, mental alertness, […]
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Licensee Unbuzzd Wellness to Host Investor Webinar on Sept. 16
September 12, 2025
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company advancing assets for neurodegenerative and metabolic disorders and alcohol misuse, announced that its licensee Unbuzzd Wellness will host an Investor Webinar on Sept. 16, 2025, at 1:30 p.m. PT / 4:30 p.m. ET. The event will feature CEO John Duffy, Advisor Jason Sawyer, Medical Director Dr. Eric […]
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Receives BUY Rating, $45 Price Target from Kingswood Capital Partners
September 10, 2025
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company developing treatments for neurodegenerative, metabolic and alcohol misuse disorders, announced that Kingswood Capital Partners has initiated coverage with a BUY rating and a US$45 price target. The valuation, based on discounted cash flow, assumes successful Phase 2 and 3 trials of lead candidate Lucid-MS between 2026 and […]
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) Provides Corporate Update
August 21, 2025
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91), a biopharmaceutical company developing treatments for neurodegenerative, metabolic and alcohol misuse disorders, announced several corporate actions. On Aug. 12, 2025, the board approved settlement of $26,812.50 in outstanding debt through the issuance of 1,102 Class B shares at a deemed price of $24.33 per share. On Aug. 15, […]
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) to Seek Shareholder Approval for $600K Private Placement
August 12, 2025
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company focused on innovative assets and biotech solutions, will seek shareholder approval for its previously announced non-brokered private placement of class A multiple voting shares (MVS) for gross proceeds of up to $600,000 at its annual general and special meeting on September 26, 2025. The Company expects the […]
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Signs CDMO Agreement for Oral Lucid-MS in Phase 2 MS Trial
August 11, 2025
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) announced that its subsidiary, Huge Biopharma Australia Pty Ltd., has signed an agreement with a leading contract development and manufacturing organization to produce an oral formulation of Lucid-MS for the company’s upcoming Phase 2 clinical trial. The trial will evaluate Lucid-MS as a potential treatment to help restore mobility in […]
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) PET Tracer Shows Potential for Monitoring Myelin Integrity in Multiple Sclerosis
August 8, 2025
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) announced that a Positron Emission Tomography (“PET”) tracer used in collaboration with Massachusetts General Hospital (“MGH”) demonstrated the ability to detect differences across lesions in multiple sclerosis (“MS”) patients that are not visible on conventional MRI. Published Aug. 5, 2025, in the European Journal of Nuclear Medicine and Molecular Imaging, […]
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Reports Positive Phase 1 Safety Results for Lucid-MS
August 5, 2025
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) announced that its Australian subsidiary has received the clinical study report for a Phase 1 multiple ascending dose trial of Lucid-MS. The report confirmed no safety or tolerability concerns in healthy participants. Lucid-MS is a patented, first-in-class, non-immunomodulatory neuroprotective compound targeting multiple sclerosis by preventing demyelination. The results support advancement […]
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Opposes Motion to Dismiss in $700 Million Market Manipulation Lawsuit
August 4, 2025
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) has filed a memorandum of law opposing a joint motion to dismiss submitted by CIBC World Markets and RBC Dominion Securities in U.S. District Court. The filing responds to a June motion to dismiss Quantum’s amended complaint, which alleges that the defendants and others engaged in market manipulation through “spoofing” […]
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Portfolio Company Unbuzzd Wellness Launches $5 Million Regulation D Offering
July 31, 2025
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company focused on building innovative biotech assets, announced that portfolio company Unbuzzd Wellness Inc. has launched a Regulation D 506(c) offering to raise up to US$5 million to fund growth and advance toward a potential initial public offering. The capital raise will not dilute Quantum BioPharma shareholders due […]
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Acquires GameStop Shares as Part of Strategic Market Integrity Campaign
July 22, 2025
Quantum BioPharma (NASDAQ: QNTM), a biopharmaceutical company focused on neurodegenerative therapies, has purchased 2,000 shares of GameStop Corp. (NYSE: GME) as a strategic balance sheet investment. The move supports the company’s broader mission to combat market corruption and advocate against manipulative trading practices. Quantum BioPharma has taken legal action seeking over $700 million in damages for […]
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Submits MS Drug Candidate to UK ILAP Program
July 8, 2025
Quantum BioPharma (NASDAQ: QNTM), announced that its subsidiary, Huge Biopharma Australia Pty Ltd., has submitted its patented multiple sclerosis drug candidate Lucid-21-302 (Lucid-MS) to the UK’s Innovative Licensing and Access Pathway (ILAP) Passport program. Aimed at accelerating access to groundbreaking treatments, the ILAP program unites developers, regulators, and the NHS to streamline drug development and approval. […]
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Launches $600 Private Placement of Class A Multiple Voting Shares
June 30, 2025
Quantum BioPharma (NASDAQ: QNTM), a biopharmaceutical company focused on innovative biotech assets, announced a non-brokered private placement of class A multiple voting shares (MVS) at $50 per share for gross proceeds of up to $600. The offering is expected to be fully subscribed by existing MVS holders, including entities linked to CEO Zeeshan Saeed and director […]
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Backs Unbuzzd’s $5 Million Raise via Regulation D Offering
June 26, 2025
Quantum BioPharma (NASDAQ: QNTM) a biopharma company focused on biotech innovation, announced that portfolio company Unbuzzd Wellness Inc. has partnered with MZ Digital and Dealmaker to raise up to $5 million through a Regulation D 506(c) offering. Unbuzzd, the maker of unbuzzd(TM)—a beverage designed to speed alcohol metabolism and reduce hangover symptoms—plans to use the funds […]
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Advances Brain and Alcohol Health Pipeline, Receives Phase 2 Trial Approval for FSD202
June 18, 2025
Quantum BioPharma (NASDAQ: QNTM) continues to advance its pipeline targeting brain disorders and alcohol health, with Singular Research highlighting new clinical milestones and strategic updates. The company secured human ethics approval for a Phase 2 trial of FSD202 in patients with Idiopathic Mast Cell Activation Syndrome, marking progress in addressing unmet needs in inflammatory pain. Meanwhile, […]
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Begins First MS Patient Scan in MGH PET Imaging Study
June 17, 2025
Quantum BioPharma (NASDAQ: QNTM) has announced that the first multiple sclerosis patient has been scanned in a collaborative study with Massachusetts General Hospital to validate a novel PET imaging technique for tracking myelin integrity. The study uses the tracer [18F]3F4AP, developed by MGH’s Dr. Pedro Brugarolas, which has shown high sensitivity to demyelinated lesions. Scanning took […]
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Plans Special Dividend Linked to Litigation Proceeds
June 13, 2025
Quantum BioPharma (NASDAQ: QNTM) announced plans to issue a special dividend in the form of Contingent Value Rights (“CVRs”) to holders of its Class B Subordinate Voting Shares on a 1:1 basis. The CVRs will entitle shareholders to a pro rata share of between 10% and 50% of any net proceeds recovered from the company’s pending […]
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Clarifies Name, Ownership, and RTO Rumors Involving unbuzzd
June 3, 2025
Quantum BioPharma (NASDAQ: QNTM) issued a formal clarification addressing recent misinformation on social media and stock trading platforms regarding a name change and reverse takeover (RTO) involving Unbuzzd Wellness Inc. Quantum confirmed it has not changed its name to unbuzzd and is not involved in an RTO transaction. The confusion followed a May 29, 2025, release. […]